Chronic Obstructive Pulmonary Disease Treatment and Pharmacist-Led Medication Management

References

• ShihC-H, WangW-H, ChenC-M, KoW-C. <p>Hesperetin-5,7,3ʹ-O-Trimethylether Dually Inhibits Phosphodiesterase 3/4 and Methacholine-Induced Airway Hyperresponsiveness in Sensitized and Challenged Mice. Drug Des Devel Ther. 2020;14:519–526. doi:10.2147/DDDT.S227432
   PubMed Web of Science ®Google Scholar
• HashemiSY, MomenabadiV, FaramarziA, KianiA. Trends in burden of chronic obstructive pulmonary disease in Iran, 1995–2015: findings from the global burden of disease study. Arch Public Health. 2020;78:45.32509302
   PubMed Web of Science ®Google Scholar
• Chronic Obstructive Pulmonary Disease Committee, Respiratory Society, Chinese Medical Association. Guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease (2013 revision). Chin J Tuberc Respir Dis. 2013;36(4):255–264.
   Google Scholar
• ZhangL, HuangJ, DongR, FengY, ZhouM. Therapeutic potential of BLT1 antagonist for COPD: involvement of inducing autophagy and ameliorating inflammation. Drug Des Devel Ther. 2019;13:3105–3116.
   PubMed Web of Science ®Google Scholar
• GayleAV, QuintJK, FuertesEI. Understanding the relationships between environmental factors and exacerbations of COPD. Expert Rev Respir Med. 2020;1–12.
   Web of Science ®Google Scholar
• WangT, MaoL, WangJ, LiP, LiuX, WuW. Influencing factors and exercise intervention of cognitive impairment in elderly patients with chronic obstructive pulmonary disease. Clin Interv Aging. 2020;15:557–566.32368022
   PubMed Web of Science ®Google Scholar
• LiM, SunWL, ChenYR, et al. Exploration of the long-term integrated management of chronic obstructive pulmonary disease. Chin J Med Guide. 2013;15(12):2103–2104.
   Google Scholar
• VasquesF, CamporotaL, BarrettNA. Nonantibiotic pharmacological treatment of severe chronic obstructive pulmonary disease exacerbations. Semin Respir Crit Care Med. 2020;41(6):842–850.32726839
   PubMed Web of Science ®Google Scholar
• KunadharajuR, SethiS. Treatment of acute exacerbations in chronic obstructive pulmonary disease. Clin Chest Med. 2020;41(3):439–451.32800197
   PubMed Web of Science ®Google Scholar
• AzizMIA, TanLE, WuDB-C, et al. Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:3203–3231. doi:10.2147/COPD.S17347230349228
   PubMed Web of Science ®Google Scholar
• AnzuetoA, MiravitllesM. Tiotropium in chronic obstructive pulmonary disease - a review of clinical development. Respir Res. 2020;21(1):199.32727455
   PubMed Web of Science ®Google Scholar
• ShuklaD, ChakrabortyS, SinghS, MishraB. Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2009;10(14):2343–2356.19678793
   PubMed Web of Science ®Google Scholar
• BuhlR, de la HozA, XueW, SinghD, FergusonGT. Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naïve to LAMA, LABA and ICS: pooled Analysis of Four Clinical Trials. Adv Ther. 2020;37(10):4175–4189.32671684
   PubMed Web of Science ®Google Scholar
• MuroS, YoshisueH, KostikasK, OlssonP, GuptaP, WedzichaJA. Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-naïve COPD patients: A pooled analysis. Respirology. 2020;25(4):393–400.31339215
   PubMed Web of Science ®Google Scholar
• ScottDA, WoodsB, ThompsonJC, et al. Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Pulm Med. 2015;15(1):145.26559138
   PubMed Web of Science ®Google Scholar
• XiongG, XuL, WeiL, LiX. Atomization inhalation of terbutaline and budesonide efficiently improved immunity and lung function of AECOPD patients. Cell Mol Immunol. 2008;5(4):287–291.18761816
   PubMed Web of Science ®Google Scholar
• XiongXF, FanLL, WuHX, ZhuM, ChengDY. Effects of tiotropium combined with theophylline on stable COPD patients of group B, D and its impact on small airway function: A randomized controlled trial. Adv Ther. 2018;35(12):2201–2213.30415298
   PubMed Web of Science ®Google Scholar
• ZhouY, ZhongNS, LiX, et al. Tiotropium in early-stage chronic obstructive pulmonary disease. N Engl J Med. 2017;377(10):923–935.28877027
   PubMed Web of Science ®Google Scholar
• ZhengHC, LiZ. Effect of tiotropium bromide combined with doxotheophylline in the treatment of chronic obstructive pulmonary disease in stable period. Chin J Gerontol. 2018;38(1):149–150.
   Google Scholar
• WedzichaJA, DecramerM, SeemungalTA. The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J. 2012;40(6):1545–1554.22835613
   PubMed Web of Science ®Google Scholar
• CilliA, BalH, GunenH. Efficacy and safety profile of roflumilast in a real-world experience. J Thorac Dis. 2019;11(4):1100–1105.31179051
   PubMed Web of Science ®Google Scholar
• AntoniouT, GomesT, MamdaniMM, JuurlinkDN. Ciprofloxacin-induced theophylline toxicity: a population-based study. Eur J Clin Pharmacol. 2011;67(5):521–526.21234553
   PubMed Web of Science ®Google Scholar
• ZhouP, JiangSP, ZhangXG. Pharmacist’s participation in the therapy of one case of arrhythmia induced by combination of doxofylline and levofloxacin. Drug Eval. 2012;9(23):42–44.
   Google Scholar
• CaiBQ, CaiSX, ChenRC, et al. Expert consensus on acute exacerbation of chronic obstructive pulmonary disease in the People’s Republic of China. Int J Chron Obstruct Pulmon Dis. 2014;9:381–395.24812503
   PubMed Web of Science ®Google Scholar
• VogelmeierCF, CrinerGJ, MartinezFJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582.28128970
   PubMed Web of Science ®Google Scholar
• MaZ, ZhangW. Short-term versus longer duration of glucocorticoid therapy for exacerbations of chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2016;40:84–90.27506415
   PubMed Web of Science ®Google Scholar
• LiuDS, HanXD, LiuXD. Current status of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Chin Med J. 2018;131(9):1086–1091.29692381
   PubMed Web of Science ®Google Scholar
• MarzukiNM, JaebMZM, BanA, et al. Personalised management of chronic obstructive pulmonary disease (COPD): malaysian consensus algorithm for appropriate use of ICS in COPD patients. Med J Malaysia. 2020;75(6):717–721.33219183
   PubMedGoogle Scholar
• ContoliM, CorsicoAG, SantusP, et al. Use of ICS in COPD: from blockbuster medicine to precision medicine. COPD. 2017;14(6):641–647.29116901
   PubMedGoogle Scholar
• TariqSM, ThomasEC. Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers? Int J Chron Obstruct Pulmon Dis. 2017;12:1877–1882.28694698
   PubMed Web of Science ®Google Scholar
• Whittaker BrownSA, BramanS. Recent advances in the management of acute exacerbations of chronic obstructive pulmonary disease. Med Clin North Am. 2020;104(4):615–630.32505256
   PubMed Web of Science ®Google Scholar
• ChoiJ, OhJY, LeeYS, et al. Bacterial and Viral Identification Rate in Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Korea. Yonsei Med J. 2019;60(2):216–222.30666844
   PubMed Web of Science ®Google Scholar
• LlorC, MoragasA, HernándezS, BayonaC, MiravitllesM. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(8):716–723.22923662
   PubMed Web of Science ®Google Scholar
• SafarikaA, GalaniI, PistikiA, Giamarellos-BourboulisEJ. Time-kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: synergism with imipenem and colistin. Eur J Clin Microbiol Infect Dis. 2015;34(2):317–323.25192733
   PubMed Web of Science ®Google Scholar
• VermeerschK, GabrovskaM, AumannJ, et al. Azithromycin during acute chronic obstructive pulmonary disease exacerbations requiring hospitalization (BACE). A multicenter, randomized, double-blind placebo-controlled trial. Am J Respir Crit Care Med. 2019;200(7):857–868.31046405
   PubMed Web of Science ®Google Scholar
• D’AnnaSE, ManiscalcoM, CappelloF, et al. Bacterial and viral infections and related inflammatory responses in Chronic Obstructive Pulmonary Disease. Ann Med. 2020;1–39.
   Web of Science ®Google Scholar
• MolyneauxPL, MalliaP, CoxMJ, et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188(10):1224–1231.23992479
   PubMed Web of Science ®Google Scholar
• van RijnAL, van BoheemenS, SidorovI, et al. The respiratory virome and exacerbations in patients with chronic obstructive pulmonary disease. PLoS One. 2019;14(10):e0223952.31647831
   PubMed Web of Science ®Google Scholar
• JafarinejadH, MoghoofeiM, MostafaeiS, SalimianJ, Azimzadeh JamalkandiS, AhmadiA. Worldwide prevalence of viral infection in AECOPD patients: A meta-analysis. Microb Pathog. 2017;113:190–196.29038056
   PubMed Web of Science ®Google Scholar
• HeMZ, JiangYW, CaiC, ZhongSQ, ZhongNS. Cohort study of 22 cases of herpes zoster in patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease. Inter J Respir. 2011;31(20):1538–1542.
   Google Scholar
• CazzolaM, RoglianiP, CalzettaL, HananiaNA, MateraMG. Impact of mucolytic agents on COPD exacerbations: A pair-wise and network meta-analysis. COPD. 2017;14(5):552–563.28753070
   PubMedGoogle Scholar
• YamayaM, NishimuraH, NadineLK, OtaC, KuboH, NagatomiR. Ambroxol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Arch Pharm Res. 2014;37(4):520–529.23856970
   PubMed Web of Science ®Google Scholar
• YangJ, LiuC, LiL, TuX, LuZ. Red blood cell distribution width predicts pulmonary hypertension secondary to chronic obstructive pulmonary disease. Can Respir J. 2019;2019:3853454.31379981
   PubMed Web of Science ®Google Scholar
• YiLD, PengLB, TanCQ, et al. Pharmaceutical care of a patient with chronic obstructive pulmonary disease. Cent South Pharm. 2010;8(10):792–795.
   Google Scholar
• SaadjianAY, Philip-JöelFF, BarretA, LevyS, ArnaudAG. Effect of almitrine bismesylate on pulmonary vasoreactivity to hypoxia in chronic obstructive pulmonary disease. Eur Respir J. 1994;7(5):862–868.8050541
   PubMed Web of Science ®Google Scholar
• LiYF, ZhangCF, XuZQ, HanP, LianXF, ChaoYS. Effect of almitrine in treatment of COPD with respiratory failure. Med Innovation Chin. 2012;9(13):37–38.
   Google Scholar
• Sans-TorresJ, DomingoC, MorónA, RuéM, MarínA. Long-term effects of almitrine bismesylate in COPD patients with chronic hypoxaemia. Respir Med. 2003;97(6):599–605.12814142
   PubMed Web of Science ®Google Scholar
• LiuKQ, NiHB, YuCB, HuXX. Effect of different administration routes of diuretics on patients with acute exacerbation of chronic obstructive pulmonary disease. Chin J Crit Care Med. 2013;33(8):688–691.
   Google Scholar
• GhobadiH, AslaniMR, HosseinianA, FarzanehE. The correlation of serum brain natriuretic peptide and interleukin-6 with quality of life using the chronic obstructive pulmonary disease assessment test. Med Princ Pract. 2017;26(6):509–515.29131048
   PubMed Web of Science ®Google Scholar
• ZhangJ, ZhaoG, YuX, PanX. Intravenous diuretic and vasodilator therapy reduce plasma brain natriuretic peptide levels in acute exacerbation of chronic obstructive pulmonary disease. Respirology. 2012;17(4):715–720.22394412
   PubMed Web of Science ®Google Scholar
• LambertAA, LamJO, PaikJJ, Ugarte-GilC, DrummondMB, CrowellTA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015;10(6):e0128004.26042842
   PubMed Web of Science ®Google Scholar
• KikuchiS, ImaiH, TaniY, TajiriT, WatanabeN. Proton pump inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2020;8:CD013113.32844430
   PubMed Web of Science ®Google Scholar
• ChaouatA, NaeijeR, WeitzenblumE. Pulmonary hypertension in COPD. Eur Respir J. 2008;32(5):1371–1385.18978137
   PubMed Web of Science ®Google Scholar
• SakaoS. Chronic obstructive pulmonary disease and the early stage of cor pulmonale: A perspective in treatment with pulmonary arterial hypertension-approved drugs. Respir Investig. 2019;57(4):325–329.
   Web of Science ®Google Scholar
• BarnesPJ, CelliBR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165–1185.19407051
   PubMed Web of Science ®Google Scholar
• Vespasiani-GentilucciU, PedoneC, Muley-VilamuM, Antonelli-IncalziR. The pharmacological treatment of chronic comorbidities in COPD: mind the gap! Pulm Pharmacol Ther. 2018;51:48–58.29966745
   PubMed Web of Science ®Google Scholar
• MtisiTF, FrishmanWH. Beta adrenergic blocker use in patients with chronic obstructive pulmonary disease and concurrent chronic heart failure with a low ejection fraction. Cardiol Rev. 2020;28(1):20–25.31804289
   PubMed Web of Science ®Google Scholar
• National Institutes of Health, US National Library of Medicine. Morphine or Fentanyl for Refractory Dyspnea in COPD. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03834363. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. Bronchoprotection of Salbutamol in Asthma and Chronic Obstructive Pulmonary Disease. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00440245. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. Pulmonary Rehab in COPD: response to Tyvaso. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02178566. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With PH Due to COPD. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03496623. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. The Safety and Efficiency of Sildenafil in the Treatment of Severe Post-capillary Pulmonary Hypertension Caused by COPD. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03185364. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. Safety of Anti-Depressant for Chronic Obstructive Pulmonary Disease. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02813447. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. Effects of Liraglutide in Chronic Obstructive Pulmonary Disease. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03466021. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03570359. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. Arbidol for COPD Exacerbations. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03851991. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. Static Lung Hyperinflation and Sympathetic Nerve Activity-Associated Large Artery Stiffness in COPD Patients. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03611699. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. RETHINC: rEdefining THerapy In Early COPD for the Pulmonary Trials Cooperative. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02867761. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Treatment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03395002. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03152149. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. Utilizing Wearable Device to Observe the Clinical Response of COPD Patients Treated With Combined Bronchodilator and Home-based Pulmonary Rehabilitation Program. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03364829. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03949842. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. Effect of Yong Chong Cao Capsule on Outcomes in Patients With Mild to Severe COPD. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03745261. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. The Effect of Inhaled PUL-042 on Rhinovirus-induced Symptoms in Smokers With GOLD Stage 0 COPD. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03794557. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. Biological Effects of Quercetin in COPD. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03989271. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03930732. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03085485. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. Investigate the Safety, Tolerability and Pharmacokinetics of CHF6523 in Healthy and in COPD Subjects. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04032535. Accessed 12, 2021.
   Google Scholar
• ThomasCD, DupreeLH, DeLosSantosM, FerreiraJA. Evaluation of the protective effects of β-blockers in the management of acute exacerbations of chronic obstructive pulmonary disease. J Clin Pharm Ther. 2019;44(1):109–114.30311242
   PubMed Web of Science ®Google Scholar
• National Institutes of Health, US National Library of Medicine. Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03443414. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. The Effects of RPL554 in Addition to Tiotropium in COPD Patients. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03028142. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD. Available from: https://www.clinicaltrials.gov/ct2/show/results/NCT02603393. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease. Available from: https://www.clinicaltrials.gov/ct2/show/results/NCT02233543. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD. Available from: https://www.clinicaltrials.gov/ct2/show/study/NCT02038829. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00676052. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. Efficacy and Safety of AQX-1125 in Unstable COPD. Available from: https://www.clinicaltrials.gov/ct2/show/results/NCT01954628. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease. Available from: https://www.clinicaltrials.gov/ct2/show/results/NCT03064113. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease. Available from: https://www.clinicaltrials.gov/ct2/show/study/NCT02518139. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD. Available from: https://www.clinicaltrials.gov/ct2/show/results/NCT00801684. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02971293. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00606684. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia. Available from: https://www.clinicaltrials.gov/ct2/show/results/NCT01669174. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03810183. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. Effectiveness of Antibiotic Therapy for Exacerbations of Chronic Obstructive Pulmonary Disease. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00495586. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. Effect of Macrolide Antibiotics on Airway Inflammation in People With Chronic Obstructive Pulmonary Disease. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00549445. Accessed 12, 2021.
   Google Scholar
• National Institutes of Health, US National Library of Medicine. Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02105961. Accessed 12, 2021.
   Google Scholar
• NybergST, Singh-ManouxA, PenttiJ, et al. Association of Healthy Lifestyle With Years Lived Without Major Chronic Diseases. JAMA Intern Med. 2020;180(5):760–768.32250383
   PubMed Web of Science ®Google Scholar
• McRobbieH, KwanB. Tobacco Use Disorder and the Lungs. Addiction; 2020.
   Google Scholar
• HuangJ, YuanX, ZhangN, QiuH, ChenX. Music Therapy in Adults With COPD. Respir Care. 2020;07489.
   Web of Science ®Google Scholar
• GrosboisJM, GephineS, DiotAS, et al. Gender does not impact the short- or long-term outcomes of home-based pulmonary rehabilitation in patients with COPD. ERJ Open Res. 2020;6(4):00032–2020.33263025
   PubMedGoogle Scholar
• Mayoralas-AlisesS, CarrataláJM, NewD-LS. Perspectives in Oxygen Therapy Titration: is Automatic Titration the Future? Arch Bronconeumol. 2019;55(6):319–327.30414709
   PubMed Web of Science ®Google Scholar
• JacobsSS, KrishnanJA, LedererDJ, et al. Home Oxygen Therapy for Adults with Chronic Lung Disease An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202(10):e121–e141.33185464
   PubMed Web of Science ®Google Scholar
• JuanesA, GarinN, ManguesMA, et al. Impact of a pharmaceutical care programme for patients with chronic disease initiated at the emergency department on drug-related negative outcomes: a randomised controlled trial. Eur J Hosp Pharm. 2018;25(5):274–280.31157039
   PubMedGoogle Scholar
• NguyenTS, NguyenTLH, PhamTTV, HuaS, NgoQC, LiSC. Impact of pharmaceutical care in the improvement of medication adherence and quality of life for COPD patients in Vietnam. Respir Med. 2019;153:31–37.31136931
   PubMed Web of Science ®Google Scholar
• MohammedMA, MolesRJ, ChenTF. Impact of pharmaceutical care interventions on health-related quality-of-life outcomes: A systematic review and meta-analysis. Ann Pharmacother. 2016;50(10):862–881.27363846
   PubMed Web of Science ®Google Scholar
• JarabAS, AlqudahSG, KhdourM, ShamssainM, MukattashTL. Impact of pharmaceutical care on health outcomes in patients with COPD. Int J Clin Pharm. 2012;34(1):53–62.22101426
   PubMed Web of Science ®Google Scholar
• JiaX, ZhouS, LuoD, ZhaoX, ZhouY, CuiYM. Effect of pharmacist-led interventions on medication adherence and inhalation technique in adult patients with asthma or COPD: A systematic review and meta-analysis. J Clin Pharm Ther. 2020. doi:10.1111/jcpt.13126
   Web of Science ®Google Scholar
• LaymanSN, ElliottWV, RegenSM, KeoughLA. Implementation of a pharmacist-led transitional care clinic. Am J Health Syst Pharm. 2020;77(12):966–971.32374382
   PubMed Web of Science ®Google Scholar
• TommeleinE, MehuysE, Van HeesT, et al. Effectiveness of pharmaceutical care for patients with chronic obstructive pulmonary disease (PHARMACOP): a randomized controlled trial. Br J Clin Pharmacol. 2014;77(5):756–766.24117908
   PubMed Web of Science ®Google Scholar
• WeiL, YangX, LiJ, et al. Effect of pharmaceutical care on medication adherence and hospital admission in patients with chronic obstructive pulmonary disease (COPD): a randomized controlled study. J Thorac Dis. 2014;6(6):656–662.24976987
   PubMed Web of Science ®Google Scholar
• LisenbyKM, CarrollDN, PinnerNA. Evaluation of a Pharmacist-Specific Intervention on 30-Day Readmission Rates for High-Risk Patients with Pneumonia. Hosp Pharm. 2015;50(8):700–709.26823619
   PubMedGoogle Scholar
• AbdulsalimS, UnnikrishnanMK, ManuMK, et al. Impact of a Clinical Pharmacist Intervention on Medicine Costs in Patients with Chronic Obstructive Pulmonary Disease in India. Pharmacoecon Open. 2020;4(2):331–342.31368087
   PubMed Web of Science ®Google Scholar
• XinC, XiaZ, JiangC, LinM, LiG. The impact of pharmacist-managed clinic on medication adherence and health-related quality of life in patients with COPD: a randomized controlled study. Patient Prefer Adherence. 2016;10:1197–1203.27468229
   PubMed Web of Science ®Google Scholar
• DavisE, MarraC, GambleJM, et al. Effectiveness of a pharmacist-driven intervention in COPD (EPIC): study protocol for a randomized controlled trial. Trials. 2016;17(1):502.27737686
   PubMed Web of Science ®Google Scholar
• WangC, ZhouJ, WangJ, et al. Progress in the mechanism and targeted drug therapy for COPD. Signal Transduct Target Ther. 2020;5(1):248.33110061
   PubMed Web of Science ®Google Scholar
• DellogonoA, DawsonA, Piers-GambleM, VargheseJ, LewickiL. Lost in transition: pharmacist roles in identifying and evaluating medication-related problems during hospital discharge follow-up visits in a primary care setting. J Prim Care Community Health. 2020;11:2150132720917297.32450748
   PubMed Web of Science ®Google Scholar
• AbdulsalimS, UnnikrishnanMK, ManuMK, AlrasheedyAA, GodmanB, MoriskyDE. Structured pharmacist-led intervention programme to improve medication adherence in COPD patients: A randomized controlled study. Res Social Adm Pharm. 2018;14(10):909–914.29104008
   PubMed Web of Science ®Google Scholar
• HämmerleinA, MüllerU, SchulzM. Pharmacist-led intervention study to improve inhalation technique in asthma and COPD patients. J Eval Clin Pract. 2011;17(1):61–70.20807295
   PubMed Web of Science ®Google Scholar
• van der MolenT, van BovenJF, MaguireT, GoyalP, AltmanP. Optimizing identification and management of COPD patients - reviewing the role of the community pharmacist. Br J Clin Pharmacol. 2017;83(1):192–201.27510273
   PubMed Web of Science ®Google Scholar
• TommeleinE, TollenaereK, MehuysE, BousseryK. Pharmaceutical care for patients with COPD in Belgium and views on protocol implementation. Int J Clin Pharm. 2014;36(4):697–701.24858598
   PubMed Web of Science ®Google Scholar
• LiuJ, DengAP, MengLH. Introduction of the training mode for specialized clinical pharmacists in the United States. China Pharm. 2016;19(9):1721–1723.
   Google Scholar
• WhitnerJB, MuellerLA, ValentinoAS. Pharmacist-driven spirometry screening to target high-risk patients in a primary care setting. J Prim Care Community Health. 2019;10:2150132719889715.31771404
   PubMed Web of Science ®Google Scholar
• BuclinT, ThomaY, WidmerN, et al. The steps to therapeutic drug monitoring: a structured approach illustrated with imatinib. Front Pharmacol. 2020;11:177.32194413
   PubMed Web of Science ®Google Scholar
• BitarS, ThillyN, AgrinierN. Sustained adherence to ESC guideline-recommended medications is associated with lower long-term mortality in heart failure and reduced ejection fraction: insights from the EPICAL2 cohort. J Clin Pharm Ther. 2020;45(4):793–803.32460416
   PubMed Web of Science ®Google Scholar
• LiH, TanJL, LiJR, et al. A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimens. Biomed Pharmacother. 2019;116:108976.31103827
   PubMed Web of Science ®Google Scholar